Today, IntelGenx Corp, a leader in pharmaceutical films, has entered into an exclusive supply agreement with ARWAN Pharmaceuticals Industries Lebanon s.a.l. for their revolutionary product, RIZAPORT®. This agreement will provide increased access to this cutting-edge product in various countries in the Middle East and North Africa region, including Lebanon, Kuwait, Saudi Arabia, United Arab Emirates, Jordan, Iraq, Libya, Oman, Yemen, Qatar, Bahrain, Egypt, Sudan, Kenya, Nigeria, Mauritius, Cameroon, Afghanistan, Tajikistan, Kazakhstan, Turkmenistan, and Uzbekistan.
Say goodbye to the struggles of swallowing pills and chugging down glasses of water—with RIZAPORT®, a revolutionary oral thin film formulation of rizatriptan benzoate, migraine relief is just a few moments away! Developed with IntelGenx’s proprietary VersaFilm® technology, RIZAPORT® is the most effective oral triptan for migraine relief, quickly dissolving and releasing its active ingredient in the mouth with a neutral flavor. Even better, this innovative solution is especially beneficial for migraine patients who suffer from nausea or difficulty swallowing—a whopping 80% of the total population.
Under the terms of their Agreement, IntelGenx will provide the Product to ARWAN who, in turn, will possess the sole right to register and market it within the specified Territory.
Dr. Horst G. Zerbe, CEO of IntelGenx, is excited to work with ARWAN to bring the innovative product RIZAPORT® to the MENA marketplace. ARWAN is the perfect partner for this endeavor, having an in-depth knowledge of the treatment and regulatory landscape in the target country, as well as a successful track record in the region.
We are thrilled to offer this ground-breaking, straightforward treatment to migraine sufferers across the Middle East and North Africa region. Migraine prevalence in this area is comparable to other parts of the world, making this solution highly beneficial to individuals here. We look forward to helping those in need with this revolutionary solution.
Since 2009, ARWAN has been dedicated to developing and producing innovative critical care solutions. Our comprehensive product line includes new-generation anti-infectives, hematinics, anesthetics and analgesics, gastrointestinals, oncology treatments, antiasthmatics, cardiovasculars, osteoporosis solutions, and wound management modalities. We are proud to be a leader in the healthcare industry, striving to improve the lives of patients in Lebanon and around the world.
ARWAN markets reach far beyond Lebanon, covering an impressive 20 countries of the Middle East and North Africa (MENA) region, as well as Africa, where the Lebanese diaspora has helped to create and foster business relationships.